Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCFinancial_Report.xls
EX-32.1 - EX-32.1 - KERYX BIOPHARMACEUTICALS INCd748370dex321.htm
EX-31.1 - EX-31.1 - KERYX BIOPHARMACEUTICALS INCd748370dex311.htm
EX-10.1 - EX-10.1 - KERYX BIOPHARMACEUTICALS INCd748370dex101.htm
EX-31.2 - EX-31.2 - KERYX BIOPHARMACEUTICALS INCd748370dex312.htm
10-Q - 10-Q - KERYX BIOPHARMACEUTICALS INCd748370d10q.htm

Exhibit 32.2

STATEMENT OF CHIEF FINANCIAL OFFICER OF

KERYX BIOPHARMACEUTICALS, INC.

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Keryx Biopharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, James F. Oliviero, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 7, 2014

   

/s/ James F. Oliviero

    James F. Oliviero, CFA
   

Chief Financial Officer

Principal Financial and Accounting Officer